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Narcolepsy with cataplexy is characterized by daytime sleepiness, cataplexy (sudden loss of bilateral muscle tone triggered by
emotions), sleep paralysis, hypnagogic hallucinations and disturbed nocturnal sleep. Narcolepsy with cataplexy is most often
associated with human leucocyte antigen-DQB1*0602 and is caused by the loss of hypocretin-producing neurons in the hypo-
thalamus of likely autoimmune aetiology. Noting that children with narcolepsy often display complex abnormal motor behav-
iours close to disease onset that do not meet the classical definition of cataplexy, we systematically analysed motor features in
39 children with narcolepsy with cataplexy in comparison with 25 age- and sex-matched healthy controls. We found that
patients with narcolepsy with cataplexy displayed a complex array of ‘negative’ (hypotonia) and ‘active’ (ranging from perioral
movements to dyskinetic–dystonic movements or stereotypies) motor disturbances. ‘Active’ and ‘negative’ motor scores corre-
lated positively with the presence of hypotonic features at neurological examination and negatively with disease duration,
whereas ‘negative’ motor scores also correlated negatively with age at disease onset. These observations suggest that paediatric
narcolepsy with cataplexy often co-occurs with a complex movement disorder at disease onset, a phenomenon that may vanish
later in the course of the disease. Further studies are warranted to assess clinical course and whether the associated movement
disorder is also caused by hypocretin deficiency or by additional neurochemical abnormalities.
Keywords: hypotonia; movement disorder; narcolepsy with cataplexy; streptococcal infection; chorea
Abbreviations: HLA = human leucocyte antigen; PANDAS = paediatric autoimmune neuropsychiatric disorders associated with
streptococcal infections; REM = rapid eye movement
Introduction
Narcolepsy with cataplexy was first described as a condition with re-
petitive attacks of sleep and/or loss of muscle tone (Westphal, 1877).
In 1880, Ge´lineau (Ge´lineau, 1880) coined the term ‘narcolepsy’.
The disease is characterized by excessive daytime sleepiness with
repetitive and refreshing sleep attacks, cataplexy, sleep paralysis
and hypnagogic hallucinations (Yoss and Daly, 1957; American
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Academy of Sleep Medicine, 2005; Dauvilliers et al., 2007a).
Cataplexy, a symptom characterized by sudden and brief (5–30 s)
losses of muscle tone (partial or total) triggered by emotions such as
laughter and surprise, is considered pathognomonic of narcolepsy
with cataplexy (American Academy of Sleep Medicine, 2005;
Vetrugno et al., 2010). Additionally, nocturnal sleep in narcolepsy
with cataplexy is not only fragmented by frequent awakenings, but
also disturbed by symptoms reflecting abnormal motor control
during sleep, such as periodic and non-periodic limb movements,
restless legs syndrome and rapid eye movement (REM) sleep be-
haviour disorder (Ferri et al., 2006, 2008; Dauvilliers et al., 2007b;
Mattarozzi et al., 2008; Knudsen et al., 2010; Plazzi et al., 2008a,
2010).
A loss of hypocretin-producing neurons (De Lecea et al., 1998;
Sakurai et al., 1998) in the postero-lateral hypothalamus (Peyron
et al., 2000; Thannickal et al., 2000) is characteristic of narcolepsy
with cataplexy. Hypocretin-producing neurons have widespread
projections within the CNS and play a key role in the regulation of
sleep and wakefulness (Saper et al., 2005), thus explaining the
major symptoms of narcolepsy with cataplexy. Animals with gen-
etic modifications in hypocretin or the hypocretin receptor gene
have narcolepsy and cataplexy, indicating causality for major nar-
colepsy symptoms (Chemelli et al., 1999; Lin et al., 1999).
Recent works strongly suggest that the loss of hypocretin
neurons is of autoimmune origin. Indeed, as for many other auto-
immune diseases, the disorder is strongly associated with human
leucocyte antigen (HLA)-DQB1*0602 (Mignot et al., 1994), with
modulating influences of other HLA subtypes (Mignot et al., 2001;
Hong et al., 2006b; Hor et al., 2010). In addition, immune-related
polymorphisms in the T-cell receptor  (Hallmayer et al., 2009;
Hor et al., 2010) and the P2YR11 receptor loci (Kornum et al.,
2011), a gene modulating immune cell function, are also asso-
ciated with the condition. Finally, high levels of anti-tribbles 2
autoantibodies and anti-streptolysin O antibodies are fo-
und around disease onset in many patients (Aran et al., 2009;
Cvetkovic-Lopes et al., 2010; Kawashima et al., 2010; Toyoda
et al., 2010). These findings suggest that it may be possible to
stop the progression of hypocretin cell loss in some patients using
immune suppressive therapy in cases close to symptom onset
when hypocretin cell damage may not yet be irreversible
(Fontana et al., 2010). To date, however, immunoglobulin treat-
ment in such cases has met with variable results (Lecendreux
et al., 2003; Dauvilliers et al., 2004, 2009; Valko et al., 2008;
Plazzi et al., 2008b).
Narcolepsy with cataplexy is a lifelong disorder arising mainly in
young adults (Dauvilliers et al., 2001) or in children (Yoss and
Daly, 1960; Aran et al., 2010); 5% of cases occur in the
pre-pubertal stage (Nevsimalova, 2009). It is typically diagnosed
10–15 years after symptom onset (Morrish et al., 2004; Ohayon
et al., 2005), although this is rapidly improving with increased
awareness. As a consequence, most case series have characterized
the disorder in adults after a long period of adaptation since onset,
and thus the phenotype at presentation has been assessed only
retrospectively. Cataplexy generally occurs within a year from
sleepiness onset, but a delay between sleepiness and cataplexy of
up to several decades, mostly in adult-onset cases with mild dis-
ease (Rye et al., 1998; Ohayon et al., 2005b), has been reported.
In recent work in our centre, we have seen increasing numbers of
children who were identified close to disease onset. In these cases,
we found that childhood cataplexy often appears abruptly as both
emotionally triggered episodes (e.g. watching cartoons, tickling),
as in adults, as spontaneous falls to the ground (e.g. while walk-
ing, running, eating), or as generalized hypotonia with prominent
facial involvement resulting in ‘cataplectic facies’ (Plazzi et al.,
2006; Serra et al., 2008; Dhondt et al., 2009; Merino-Andreu
and Martinez-Bermejo, 2009; Peraita-Adrados et al., 2011).
Overall, 11 cases of cataplectic status with typical cataplectic facies
have been reported in children (Hecht et al., 2003; Plazzi et al.,
2006; Serra et al., 2008; Dhondt et al., 2009; Merino-Andreu and
Martinez-Bermejo, 2009; Peraita-Adrados et al., 2011). This pic-
ture is generally associated with hypotonia, ptosis, tongue protru-
sion or unsteady gait at neurological examination (Plazzi et al.,
2006; Serra et al., 2008; Dhondt et al., 2009), and rarely with
‘unconscious’ active motor behaviours (e.g. scratching, head shak-
ing) that have been only briefly characterized (Serra et al., 2008).
Precocious puberty has also been reported in 3 out of 11 children
(Plazzi et al., 2006; Peraita-Adrados et al., 2011), whereas obesity
occurs at least in 25% of paediatric patients (Nevsimalova, 2009).
In an effort to document cataplexy features using video record-
ings, we noticed abnormal motor behaviours occurring around epi-
sodes of cataplexy with or without emotional triggering. These
abnormal behaviours included the atypical features of childhood
cataplexy described above and the occurrence of additional active,
but apparently unconscious, movements ranging from normal pat-
terns to frankly pathological motor behaviours. Indeed, given the
common association with increased anti-streptolysin O titres in
narcolepsy with cataplexy, we also searched for motor abnormal-
ities reminiscent of features often observed in Sydenham’s Chorea
and Paediatric Autoimmune Neuropsychiatric Disorders Associated
with Streptococcal infections (PANDAS), two autoimmune move-
ment disorders linked to streptococcal infection (Cardoso et al.,
2006). In this study, we report these novel features of childhood
narcolepsy with cataplexy in comparison with a gender- and age-
matched control group using representative figures and videos, and
discuss their relevance for understanding pathophysiology of nar-
colepsy with cataplexy and to aid early correct diagnosis.
Materials and methods
We performed a prospective study to describe the clinical features of
childhood narcolepsy with cataplexy at disease onset. The study was
conducted at the Sleep Disorders Centre, University of Bologna, and
approved by the local institutional review board.
Participants
We prospectively collected patients under the age of 18 years old who
were newly diagnosed with narcolepsy with cataplexy between the
years 2001–11, who met the international criteria for narcolepsy
with cataplexy (American Academy of Sleep Medicine, 2005). None
of the patients had positive family history for narcolepsy with cata-
plexy. Consent was obtained from parents and assent from patients.
Patients had a complete clinical and neurological examination, conven-
tional brain MRI and underwent a 48 h continuous polysomnographic
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recording followed by a standard five-nap Multiple Sleep Latency Test
(Littner et al., 2005). HLA-DQB1*0602 typing was conducted in all
patients, and CSF hypocretin-1 evaluations were performed when pos-
sible. All patients were drug-naı¨ve for stimulant and anti-cataplectic
drugs at the time of the study.
The presence and age of onset of all core narcolepsy with cataplexy
symptoms (sleepiness, cataplexy, sleep paralysis, hypnagogic hallucin-
ations and disturbed nocturnal sleep) and the presence of any abnorm-
alities at neurological examination were systematically documented.
Additionally, the history of tonsillectomy occurring before narcolepsy
with cataplexy symptom onset, and biochemical data pertaining to
streptococcal infections (anti-streptolysin O titres) were also collected.
Disease duration was defined as the elapsed time from the onset of
the first symptom (i.e. sleepiness or cataplexy, including ‘cataplectic
facies’) to clinical observation. We enrolled 39 patients (19 females)
with a mean  standard deviation (SD) age of 11.5  3.5 years.
Following the launch of a media awareness campaign led by the
Italian association of narcoleptic patients (Associazione Italiana
Narcolettici) in 2001, we were able to observe and diagnose an in-
creasing number of new narcolepsy with cataplexy cases every year,
and also children close to disease onset. In particular, in the years from
2001 to 2005 we diagnosed one or two children per year; in the
2-year period from 2006 to 2007, four per year; and from 2008 to
2010, up to nine per year. The mean  SD age of symptom onset was
9.3  3.0 years; yearly narcolepsy with cataplexy onset ranged from
one to three during the period from 1998 to 2006, from six to nine in
the period from 2007 to 2009 and a single patient in 2010. Diagnostic
delay was 1.8  2.1 years (range 3 weeks–9 years). Tentative diag-
noses made prior to narcolepsy with cataplexy included myopathy (two
cases), Sydenham’s chorea (three cases), PANDAS (one case), atten-
tion deficit hyperactivity disorder (three cases), epilepsy (six cases),
malingering (one case), encephalitis (three cases) and depression
(two cases). All patients had excessive daytime sleepiness (onset:
9.3  3.0 years) and cataplexy (onset: 10.0  3.1 years). Sleep paraly-
sis was present in 26% (onset: 9.8  4.8 years), hypnagogic hallucin-
ations in 59% (onset: 10.4  3.5 years) and disturbed nocturnal sleep
in 51% (onset: 9.7  3.0 years) of cases. A mean  SD sleep latency
of 3.9  3.3 min and 4.2  0.9 sleep onset REM periods were found
on the Multiple Sleep Latency Test. The mean  SD Epworth sleepi-
ness scale score was 14.9  3.2. HLA-DQB1*0602 was positive in
36 out of 39 (92%) patients. CSF hypocretin-1 was 5110 pg/ml in
all the 27 tested cases (mean  SD of 24.9  29.7 pg/ml), including
three DQB1*0602-negative patients. Eight patients (23%) had a clin-
ical history of allergy (atopic dermatitis, allergic asthma and allergic
rhinitis), while two (7%) had evidence of tonsillectomy occurring be-
fore the onset of narcolepsy with cataplexy symptoms. Mean  SD
anti-streptolysin O values were 333  254, and 33% had levels
4400. Conventional brain MRI findings were unremarkable.
Interictal neurological examination revealed frequently overlapping
abnormal findings in 17 cases (44%): 16 patients (41%) had mildly
reduced muscle tone overall and 10 subjects (26%) had an abnormal
gait, characterized by wide-based swaying. Overall, nine children
(23%) had a combination of hypotonia and abnormal gait, whereas
seven (18%) and one (3%) presented only mild hypotonia or abnor-
mal gait, respectively. The rest of the examination was unremarkable.
Twenty-five healthy controls were also enrolled. They were matched
to patients for gender (52% males, P = 0.955), and age (mean  SD
age = 12.3  3.2 years, P = 0.408). At a clinical interview all subjects
denied symptoms of sleep disorders, and none of them had patho-
logical signs on neurological examination. Their mean  SD Epworth
sleepiness scale score was 6  2.
Video recordings
Video recordings were performed with the subject sitting and/or
standing for 10–40 min, enough for the child to feel at ease but not
long enough for sleepiness to set in. Patients were also asked to take a
brief nap prior to video recordings to reduce sleepiness, and were
asked again whether they felt sleepy at the end of the procedure;
this was done to avoid the confounding effects of sleepiness on the
observation of cataplexy. Videos of patients who reported sleepiness
during the recordings were excluded from further analysis. Prior to
each video recording, patients were interviewed (C.F., V.P.) to deter-
mine humour preference and asked to choose between various funny
videos; these were selected to best stimulate each subject. Video
recordings included a 5 min baseline recording and up to 30 min
while subjects were watching videos.
Two independent neurologists, experts in the field of movement dis-
orders and blind to patients’ or controls’ clinical features (M.J.E., P.C.),
independently analysed video recordings, rating ‘negative’ and ‘active’
motor symptoms at baseline and during emotional stimulation. The
scoring procedure of each video encompassed two steps allowing
the separate evaluation of movements occurring at baseline and
during emotional stimulation. Video recordings of patients and controls
were shown to the two raters in a random order. ‘Negative’ motor
phenomena were classified as: (i) paroxysmal head drops and falls;
(ii) persistent eyelid narrowing and tongue protrusion; (iii) persistent
facial hypotonia; and (iv) persistent generalized hypotonia. ‘Active’
motor phenomena were classified as: (i) raising of the eyebrows;
(ii) perioral and tongue movements; (iii) facial grimaces; (iv) swaying
of the head and/or trunk; (v) stereotyped motor behaviour; and
(vi) dyskinetic or dystonic movements. Each item was scored on an
ordinal scale ranging from 0 (absent) to 3 (continuously present).
Statistical analysis
Clinical, polygraphic and laboratory data are reported as frequencies or
mean  SD.
Inter-observer reliability estimates for each motor phenomenon score
were assessed by Cohen’s  statistics. According to Fleiss (Fleiss,
1981), a 4 0.75 indicates excellent agreement between the two
scorers, whereas a  between 0.40 and 0.75 suggests a fair to good
agreement, and a 5 0.40 a poor agreement.
A composite score of ‘negative’ (range 0–12) and ‘active’ (range
0–18) motor features at baseline and during emotional stimulation
was then obtained by summing each sub-item score for each rater.
A mean value between the two scorers for each ‘negative’ and ‘posi-
tive’ motor feature and for the composite scores was calculated, and
this mean score was used for comparison between patients and con-
trols using the Mann–Whitney U-test.
Mean scores at baseline and during emotional stimulation conditions
were compared using the Wilcoxon signed-rank test for both patients
and controls. Additionally, the difference between each score after
emotional trigger and at baseline was calculated for each motor fea-
ture, and a comparison between patients and controls was then per-
formed using the Mann–Whitney U-test.
Associations between motor phenomena scores in patients with and
without pathological signs at neurological examination (hypotonia-
and/or wide-based swaying gait) and with or without elevated anti-
streptolysin O titres (i.e. 4400) were tested using Mann–Whitney
U-tests.
The relationships between motor phenomena scores, age at narco-
lepsy with cataplexy onset, disease duration, sleepiness severity at
Multiple Sleep Latency Test (sleep latency, number of sleep-onset
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REM periods), CSF hypocretin-1 and plasma anti-streptolysin O values
were assessed using Spearman’s correlation analysis.
A P4 0.05 was considered to be statistically significant.
Results
Motor phenomena assessment:
inter-observer reliability estimates
Mean, median and SD of the scores of each ‘negative’ and ‘posi-
tive’ motor phenomenon assessed by each observer are reported
in Supplementary Table 1, together with inter-observer reliability
estimates according to  statistics. Reliability was in the excellent
range for most of the motor phenomena assessed, good for some
motor scores (facial hypotonia after emotional trigger, perioral and
tongue movements at baseline, facial grimacing after emotional
trigger and stereotyped motor behaviour at baseline), and on
the limit for poor agreement for a single item (facial grimacing
at baseline).
Motor phenomena assessment in
patients versus controls: the
effect of emotional trigger
Mean values of ‘negative’ and ‘active’ motor phenomena scores at
baseline and during emotional stimuli are reported in Table 1 for
both patients and controls, together with statistical comparison
using Mann–Whitney U-tests.
All ‘negative’ motor phenomena and the composite score eval-
uated at baseline and during emotional stimuli were significantly
more common in the patients, with only a single control partici-
pant showing an isolated brief head drop during emotional stimuli
(Fig. 1; Supplementary Videos 1–3]. Patients and controls obtained
a mean score 51 in the following percentages at baseline and
during emotional stimuli, respectively: head drops and falls, 18 and
82% versus 0 and 4%; ptosis and tongue protrusion, 51 and 82%
versus 0 and 0%; facial hypotonia, 39 and 71% versus 0 and 0%;
and generalized hypotonia, 31 and 47% versus 0 and 0%.
All the ‘active’ motor phenomena except facial grimacing at
baseline were significantly more common in patients compared
with controls (Fig. 2; Supplementary Videos 4–8]. The ‘active’
composite score was also significantly higher in patients compared
with controls. Patients and controls obtained a mean score 51 in
the following percentages at baseline and during emotional sti-
muli, respectively: eyebrow raising, 23 and 76% versus 0 and
36%; perioral and tongue movements, 39 and 100% versus 20
and 68%; facial grimaces, 10 and 82% versus 0 and 36%; head/
trunk swaying, 36 and 90% versus 0 and 12%; stereotyped motor
behaviour, 13 and 61% versus 0 and 16%; and dyskinetic–
dystonic movements, 10 and 55% versus 0 and 8%.
Two additional abnormal complex behaviours could not be
simply classified as ‘active’ or ‘negative’ motor phenomena: (i) a
posture characterized by neck extension, eyelid ptosis with eye-
brow raising while watching videos (‘neck extension viewing’)
observed exclusively in nine patients (24%); and (ii) a rapid and
rhapsodic set of choreic movements of the whole body and limbs
with hypotonia that closely recalled the motion of puppets
observed exclusively in five patients (13%) (‘puppet-like’ move-
ments; Supplementary Videos 9 and 10). These complex behav-
iours were scored as present/absent during video recordings,
without further differentiating their frequency or the impact of
the emotional trigger.
We tested the impact of emotional stimuli on motor phenomena
in patients and controls comparing the scores at baseline and
during emotional stimulation for each group using the Wilcoxon
Table 1 Motor phenomena scores in patients and controls
Motor
phenomena
Narcolepsy
with
cataplexy,
mean  SD
Controls,
mean  SD
P-value
Negative
Head drop and falls
Baseline 0.31  0.72 0.00  0.00 0.017
Trigger 1.25  0.84 0.04  0.20 50.0005
Ptosis and tongue protrusion
Baseline 0.78  0.83 0.00  0.00 50.0005
Trigger 1.66  0.86 0.00  0.00 50.0005
Facial hypotonia
Baseline 0.73  0.94 0.00  0.00 50.0005
Trigger 1.42  0.93 0.00  0.00 50.0005
Generalized hypotonia
Baseline 0.55  0.90 0.00  0.00 0.001
Trigger 0.88  1.02 0.00  0.00 50.0005
Positive
Eyebrow raising
Baseline 0.29  0.52 0.02  0.10 0.013
Trigger 1.11  0.81 0.44  0.46 0.001
Perioral and tongue movements
Baseline 0.55  0.64 0.26  0.41 0.047
Trigger 1.59  0.59 0.74  0.50 50.0005
Facial grimaces
Baseline 0.22  0.55 0.08  0.19 0.404
Trigger 1.12  0.68 0.50  0.43 50.0005
Head/trunk swaying
Baseline 0.42  0.53 0.00  0.00 50.0005
Trigger 1.29  0.72 0.14  0.34 50.0005
Stereotyped motor behaviour
Baseline 0.22  0.44 0.02  0.10 0.024
Trigger 0.82  0.80 0.30  0.38 0.006
Dyskinetic–dystonic movements
Baseline 0.13  0.32 0.00  0.00 0.041
Trigger 0.74  0.71 0.12  0.30 50.0005
Consistent patterns
Neck extension viewing 0.24  0.43 0.00  0.00 0.009
Puppet-like behaviour 0.13  0.34 0.00  0.00 0.064
Composite scores
Composite negative
Baseline 2.37  3.21 0.00  0.00 50.0005
Trigger 5.21  3.33 0.04  0.20 50.0005
Composite active
Baseline 1.83  2.35 0.38  0.46 0.001
Trigger 5.55  2.69 1.80  1.05 50.0005
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signed-rank test. Patients showed a significant increase in all the
‘negative’ and ‘active’ motor phenomena during the emotional
stimuli, whereas controls displayed a significant increase of most
of the ‘active’ motor features (Table 2, first two columns). To
better dissect the effect of emotional stimulation in the two popu-
lations, we calculated the difference (delta) between baseline and
emotional stimulation conditions for each motor phenomenon,
and we then compared these values between patients and controls
using Mann–Whitney U-tests. Patients showed significantly higher
deltas for all the ‘negative’ and ‘active’ motor phenomena during
emotional stimuli (Table 2) compared with control participants.
Motor phenomena assessment
in patients: relation to baseline
neurological examination findings
Dichotomizing our narcolepsy with cataplexy population on the
presence or absence of subtle alterations at neurological examin-
ation (mild hypotonia and/or wide based swaying gait), we found
that the 17 patients with narcolepsy with cataplexy presenting
with such abnormalities showed: (i) higher overall ‘negative’ and
‘active’ composite scores; (ii) higher scores for all the ‘negative’
motor phenomena; (iii) higher scores for most ‘active’ motor phe-
nomena occurring in the facial area (raising of the eyebrows, facial
grimacing), and involving postural control (swaying of the head or
trunk); and (iv) more frequently had the patterns of ‘neck exten-
sion viewing’ and ‘puppet-like movements’ (Table 3).
Patients with and without abnormalities at neurological exam-
ination obtained a mean score 51 in the following percentages at
baseline and during emotional stimuli, respectively: head drops
and falls, 35 and 100% versus 4 and 68%; ptosis and tongue
protrusion, 82 and 94% versus 27 and 91%; facial hypotonia,
77 and 94% versus 9 and 54%; generalized hypotonia, 65 and
81% versus 4 and 23%; eyebrow raising, 47 and 100% versus 4
and 59%; perioral and tongue movements, 47 and 100% versus
32 and 100%; facial grimaces, 12 and 100% versus 9 and 68%;
head/trunk swaying, 53 and 94% versus 23 and 86%; stereo-
typed motor behaviour, 18 and 69% versus 9 and 54%; and
dyskinetic–dystonic movements, 18 and 56% versus 4 and 54%;
Figure 1 ‘Negative’ motor phenomena. (A) Head drop: sequence of head drop while watching cartoons in one patient. (B) Persistent
eyelid narrowing and tongue protrusion in three different cases. (C) Persistent facial hypotonia in three subjects. (D) Persistent generalized
hypotonia in three patients: wide-based gait (left), hypotonia leading to forced squatting position (centre) and unsteady gait (right).
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Figure 2 ‘Active’ motor phenomena. (A) Raising of the eyebrows in three different subjects. (B) Perioral and tongue movements: lip
licking (left), lip biting (centre) and lip chewing (right). (C) Facial grimaces: asymmetric facial contraction (left), repetitive tongue pro-
trusion (centre) and asymmetric mouth contraction (right). (D) Swaying of the head and/or trunk: swaying of the head (left), swaying of
the head and trunk (centre) and neck extension viewing (right). (E) Stereotyped motor behaviour: repetitive/rhythmic bilateral finger
movements with mouth stimulation (left), bilateral repetitive/rhythmic arms and hands movements (centre) and rhythmic purposeless
finger tapping on the lips (right). (F) Dyskinetic or dystonic movements: sequence of choreic trunk and limb movements in a patient.
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‘neck extension viewing’, 50% versus 4%; and ‘puppet-like’
movements 29% versus 0%.
Correlations of motor phenomena
scores with age at onset, disease
duration, multiple sleep latency
test data, and cerebrospinal fluid
hypocretin-1 levels
We tested whether the observed motor features correlated with
severity or clinical presentation of narcolepsy with cataplexy. To
do so, we performed a Spearman’s correlation analysis between
age at onset and time from narcolepsy with cataplexy onset, sleep
latency and sleep-onset REM period numbers during the Multiple
Sleep Latency Test, CSF hypocretin-1 levels and the composite
scores of ‘negative’ and ‘active’ motor phenomena. We found
that the age at narcolepsy with cataplexy onset was inversely
related to ‘negative’ composite scores, and that disease duration
was inversely related to both ‘negative’ and ‘active’ composite
scores, the latter reaching statistical significance only during emo-
tional stimulation (Fig. 3). No other significant correlations (sleep
latency and sleep-onset REM periods at Multiple Sleep Latency
Test, hypocretin-1 levels) to composite scores were found (Table 4).
Motor phenomena in patients with
and without biochemical evidence
of past streptococcal infections
Motor phenomena scores were assessed with relation to biochem-
ical evidence suggesting recent streptococcal infection. This com-
parison was performed between 13 patients with, and 26 patients
without increased anti-streptolysin O titres (i.e. 4400) at first as-
sessment. Patients with anti-streptolysin O levels of 4400 showed
higher composite scores for some ‘active’ motor features at base-
line and during emotional stimulation, and scored particularly high
in subscales involving facial muscles (perioral and tongue move-
ments, and facial grimacing), as well as in the ‘active’ composite
score at baseline. In contrast, anti-streptolysin O-positive patients
did not differ from negative patients on any of the ‘negative’
motor features score (Table 3). Spearman’s analysis did not
show a significant relationship between anti-streptolysin O titres
and the composite scores (Table 4). These results did not change
when the two patients that underwent tonsillectomy before the
onset on narcolepsy with cataplexy were excluded (data not
shown).
Discussion
In this study, we found that cataplexy in children close to narco-
lepsy with cataplexy onset commonly presents as a complex move-
ment disorder that includes not only ‘negative’ (hypotonic) motor
features but also ‘active’ movement abnormalities. This presenta-
tion likely evolves into cataplexy with usual emotional triggers
such as laughing (American Academy of Sleep Medicine, 2005)
as previously reported (Serra et al., 2008). ‘Negative’ features
ranged from partial (with ptosis and tongue protrusion in 51%,
and facial hypotonia in 39% of cases) to generalized hypotonia
(31% of our population, also evident at the neurological examin-
ation in 41% of children), generally enhanced by emotional trig-
gering, thus consistent with the classic definition of cataplexy. In
addition, ‘active’ motor phenomena were also observed, including
eyebrow raising (23%), perioral and tongue movements (39%),
facial grimacing (10%), body swaying (36%), dyskinetic and/or
dystonic movements of the arms and of the tongue (10%), and
stereotyped motor behaviours (13%). ‘Active’ phenomena were
also increased by emotional stimulation, suggesting a link with
genuine cataplexy. Both ‘negative’ and ‘active’ motor phenomena
correlated inversely with disease duration, suggesting increased
severity around onset, whereas ‘negative’ motor phenomena in-
versely correlated with age at narcolepsy with cataplexy onset,
Table 2 Impact of emotional stimulation on motor phenomena scores of patients and controls
Motor phenomena Narcolepsy
with cataplexy,
P-value
Controls,
P-value
Narcolepsy
with cataplexy,
mean  SD
Controls,
mean  SD
P-value
Head drop and falls 0.000 0.317 1.01  0.63 0.04  0.20 50.0005
Ptosis and tongue protrusion 0.000 1.000 0.93  0.48 0.00  0.00 50.0005
Facial hypotonia 0.000 1.000 0.75  0.42 0.00  0.00 50.0005
Generalized hypotonia 0.000 1.000 0.39  0.51 0.00  0.00 50.0005
Eyebrow raising 0.000 0.001 0.80  0.50 0.42  0.49 0.004
Perioral and tongue movements 0.000 0.001 1.03  0.35 0.48  0.57 50.0005
Facial grimaces 0.000 0.001 0.89  0.47 0.42  0.43 50.0005
Head/trunk swaying 0.000 0.059 0.86  0.45 0.14  0.34 50.0005
Stereotyped motor behaviour 0.000 0.004 0.59  0.59 0.28  0.38 0.037
Dyskinetic–dystonic movements 0.000 0.063 0.63  0.55 0.12  0.30 50.0005
Composite negative 0.000 0.317 3.09  1.58 0.04  0.20 50.0005
Composite active 0.000 0.000 3.70  1.49 1.42  1.20 50.0005
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suggesting a discrete phenotype of childhood narcolepsy with
cataplexy.
Our study extends previous preliminary observations (Serra
et al., 2008; Peraita-Adrados et al., 2011) documenting general-
ized hypotonia and prominent facial involvement (‘cataplectic
facies’) in childhood cataplexy close to disease onset. Most not-
ably, we found that facial hypotonia in these cases commonly
presents as continuous muscular weakness affecting the jaw
(‘cataplectic gape’, intermittent or continuous jaw opening/drop-
ping with tongue protrusion) or the eyelids (ptosis), with all these
features enhanced by emotions. This presentation was highly
stereotyped and specific for rapidly evolving narcolepsy with cata-
plexy, suggesting it is a direct reflection of an acute failure of
hypocretinergic neurotransmission. In this context, the prominent
facial involvement may reflect the primary importance of the
hypocretinergic facilitation of motoneuron activity at the level of
Table 3 Comparison of motor phenomena in patients with and without hypotonic features at neurological examination and
with or without increased anti-streptolysin O titres at presentation
Motor phenomena Normal
neurological
examination
(n = 22),
mean  SD
Hypotonic
neurological
examination
(n = 17),
mean  SD
P-value Anti-streptolysin
O 5 400 (n = 26),
mean  SD
Anti-streptolysin
O4 400 (n = 13),
mean  SD
P-value
Negative
Head drop and falls
Baseline 0.05  0.21 0.65  0.98 0.005 0.21  0.64 0.5  0.87 0.237
Trigger 0.86  0.71 1.78  0.73 0.001 1.14  0.77 1.46  0.97 0.336
Ptosis and tongue protrusion
Baseline 0.34  0.45 1.35  0.88 50.0005 0.65  0.76 1.04  0.95 0.216
Trigger 1.20  0.57 2.28  0.80 50.0005 1.48  0.84 2  0.82 0.105
Facial hypotonia
Baseline 0.16  0.32 1.47  0.98 50.0005 0.60  0.82 1  1.14 0.280
Trigger 0.89  0.55 2.16  0.85 50.0005 1.30  0.92 1.65  0.94 0.282
Generalized hypotonia
Baseline 0.07  0.23 1.18  1.06 50.0005 0.40  0.75 0.85  1.13 0.167
Trigger 0.27  0.53 1.72  0.95 50.0005 0.76  0.96 1.12  1.14 0.321
Positive
Eyebrow raising
Baseline 0.05  0.21 0.62  0.63 50.0005 0.17  0.37 0.54  0.69 0.059
Trigger 0.70  0.63 1.66  0.70 50.0005 0.94  0.68 1.42  0.95 0.111
Perioral and tongue movements
Baseline 0.39  0.46 0.76  0.77 0.094 0.35  0.44 0.96  0.78 0.006
Trigger 1.43  0.50 1.81  0.66 0.068 1.44  0.49 1.88  0.68 0.046
Facial grimaces
Baseline 0.14  0.32 0.32  0.75 0.419 0.08  0.23 0.5  0.84 0.014
Trigger 0.86  0.52 1.47  0.74 0.004 0.92  0.43 1.5  0.91 0.035
Head/trunk swaying
Baseline 0.25  0.43 0.65  0.58 0.021 0.35  0.46 0.58  0.64 0.281
Trigger 1.00  0.53 1.69  0.77 0.002 1.22  0.71 1.42  0.76 0.400
Stereotyped motor behaviour
Baseline 0.14  0.32 0.32  0.56 0.222 0.15  0.31 0.35  0.63 0.460
Trigger 0.59  0.59 1.13  0.96 0.058 0.70  0.60 1.04  1.09 0.479
Dyskinetic–dystonic movements
Baseline 0.05  0.21 0.24  0.40 0.040 0.12  0.33 0.15  0.32 0.433
Trigger 0.55  0.51 1.00  0.88 0.136 0.68  0.68 0.85  0.8 0.564
Consistent patterns
Neck extension viewing 0.05  0.21 0.50  0.52 0.001 0.24  0.44 0.23  0.44 0.950
Puppet-like behaviour 0.00  0.00 0.29  0.47 0.007 0.12  0.33 0.15  0.38 0.738
Composite scores
Composite negative
Baseline 0.61  0.84 4.65  3.70 50.0005 1.87  2.79 3.38  3.83 0.177
Trigger 3.23  1.91 7.94  2.92 50.0005 4.68  3.16 6.23  3.54 0.175
Composite active
Baseline 1.00  1.19 2.91  3.01 0.008 1.21  1.27 3.08  3.4 0.025
Trigger 4.43  1.47 7.09  3.23 0.004 4.96  1.91 6.69  3.58 0.160
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the multiply-innervated muscle fibres of the facial muscles
(Schreyer et al., 2009) and of the trigeminal motor nuclei
(Mascaro et al., 2009), while the mild generalized hypotonia
could correspond to an abrupt general lack of facilitation of
spinal cord motoneurons (Yamuy et al., 2004).
For the first time, we have described and documented though
videotaping a wide range of ‘active’ movements in childhood nar-
colepsy with cataplexy in patients close to disease onset. These
were represented by both an increase in normal purposeful move-
ments (e.g. lip licking) and the occurrence of purposeless move-
ments (e.g. dyskinetic–dystonic arm movements, tongue
movements, stereotypies). The pathophysiology of these abnorm-
alities is unknown, but it could be hypothesized that they repre-
sent a countermeasure to sleepiness, as hyperactivity is a frequent
manifestation of sleepiness in children, or to hypotonia, given the
evidence of a semi-permanent condition in a high proportion of
cases. Several points however argue against this functional
‘fighting of sleepiness’ interpretation. First, such pathological
movements have never been reported in children with daytime
sleepiness secondary to other causes (Chervin et al., 2002), and
we took great precautions to exclude daytime sleepiness during
testing (see ‘Materials and methods’ section). When asked, pa-
tients reported that they were not sleepy and never stopped
watching funny videos despite falls and movements. Secondly,
when polygraphic recordings were available, EEG patterns asso-
ciated with sleep or sleepiness were not detected. Thirdly, the
severity of the movements (intensity, frequency) did not correlate
with objective sleepiness assessments. Finally, these ‘active’ move-
ments were enhanced by emotions, suggesting they are related to
cataplexy. The reported movements are not commonly described
in adulthood cataplexy that is typically characterized by jaw drop-
ping, facial flickering or head dropping (Anic-Labat et al. 1999), as
well as by twitches of the face and of the limbs occurring during a
cataplectic spell and generally assessed by means of questionnaires
(Sturzenegger and Bassetti, 2004; Overeem et al., 2011).
Moreover, we also documented clear-cut pathological movements
(e.g. dyskinetic–dystonic patterns, grimacing, stereotipies) for the
first time in the context of narcolepsy. These findings are therefore
in favour of a complex movement disorder that overlaps with
cataplexy and occurs close to its onset in children.
We wish to highlight that we documented a single fragment of
hypotonia (i.e. head drop) during laughter in one of our controls,
and an intensification of ‘active’ movements in the stimulated
versus baseline condition in the control group as a whole. These
findings are not surprising, and in particular the former is con-
firmatory of sayings in popular use, for example ‘being weak
Figure 3 Scattered graphs of composite scores and disease duration. Scattered graphs showing the negative correlations between disease
duration and ‘negative’ motor phenomena at baseline (upper left panel), under emotional trigger (upper right panel), and between
disease duration and ‘active’ motor phenomena at baseline (lower left panel) and under emotional trigger (lower right panel).
NC = narcolepsy with cataplexy.
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with laughter’, of the occurrence of cataplexy-like phenomena in
young adults (Bassetti and Aldrich, 1996) or in non-narcoleptic
subjects (Anic-Labat et al., 1999), and of the decreased H-reflex
amplitude, a correlate of reduced muscle tone, during laughter in
normal subjects (Overeem et al., 1999) as well as in narcoleptic
patients (Lammers et al., 2000). These data suggest that laughter
induces hypotonia in healthy individuals, which in patients with
cataplexy precipitates a pattern of more severe inhibition of
normal tone (Overeem et al., 1999).
Considering the key role of dopaminergic transmission in many
movement disorders and in regulating both muscle tone and alert-
ness, we speculate that ‘active’ motor phenomena observed at
disease onset could represent the acute destabilization of dopa-
minergic–hypocretinergic interactions. It is possible that sudden
loss of hypocretinergic activity engages dopaminergic transmission
to compensate for hypersomnia and hypotonia, resulting in tem-
porary instability, a model suggested by both anatomical and
pharmacological experiments. Indeed, hypocretinergic neurons
have direct dopaminergic efferents (e.g. via the ventro-tegmental
area to the medial prefrontal cortex, or activating the mesolimbic
dopamine pathway) (Fadel and Deutch, 2002; Vittoz and Berridge,
2006; Narita et al., 2006; Vittoz et al., 2008), and are also modu-
lated by dopamine (Bubser et al., 2005; Alberto et al., 2006).
Dopaminergic transmission is essential for the stimulant effect of
modafinil and amphetamines (Nishino and Mignot, 1997;
Kanbayashi et al., 2000; Wisor et al., 2001; Wisor and Eriksson,
2005; Madras et al., 2006; Murillo-Rodr|guez et al., 2007; Qu
et al., 2008). Further, cataplexy is modulated by D2/D3 receptors
and sleep attacks by D1 receptors in mice (Burgess et al., 2010).
Blockade or activation of D2/D3 receptors improves or aggra-
vates cataplexy, respectively, without modifying REM sleep in
canine narcolepsy (Okura et al., 2000, 2004). Dopaminergic
drugs acting on D2/D3 receptors in the ventral tegmental area
and the globus pallidus/putamen, as well as dopaminergic drugs
acting on D3 receptors in the substantia nigra increase cataplexy
without affecting sleep in canine narcolepsy with cataplexy (Reid
et al., 1996; Honda et al., 1999).
Conflicting studies have shown either the presence (Eisensehr
et al., 2003) or the absence (MacFarlane et al., 1997; Rinne
et al., 2004) of in vivo alterations of the human striatal dopamin-
ergic system in adult narcolepsy with cataplexy, and a significant
impact of stimulant treatment on dopaminergic transmission
(Staedt et al., 1996; Volkow et al., 2009). The most consistent
monoaminergic abnormality reported in canine narcolepsy has
been increased dopamine content in the amygdala (Miller et al.,
1990). Cerebral single-photon emission CT during cataplexy dis-
closed increased perfusion of different cortico-subcortical networks
consistently encompassing the basal ganglia (Hong et al., 2006a;
Chabas et al., 2007), and frequently involving the right amygdala
(Hong et al., 2006a), a structure functionally activated during
cataplexy (Gulyani et al., 2002). Functional MRI studies in adult-
hood narcolepsy with cataplexy have shown altered emotional
processing with increased right amygdala activity (Schwartz
et al., 2008; Reiss et al., 2008), and correlations between disease
duration and activation of the ventral–medial prefrontal cortex
(Ponz et al., 2010), a cerebral structure involved in conflict moni-
toring and motor inhibition (Brass et al., 2007), and found to be
abnormal in narcolepsy with cataplexy (Kim et al., 2008). It is
therefore possible that the complex movement disorder we have
described in childhood narcolepsy with cataplexy close to disease
onset results from increased dopaminergic transmission and the
transient imbalance of basal ganglia and cortical networks.
Altered emotional processing engaging cortico-subcortical net-
works may also be involved in the transition to clear-cut cataplexy
(Schwartz et al., 2008; Ponz et al., 2010).
The association between ‘active’ motor phenomena and evidence
of recent streptococcal infection was the second notable finding of
this study. We wish to indicate that the cases reported in this study
occurred prior to 2009–10, and thus are unlikely to involve H1N1
vaccination or the H1N1 pandemic previously involved in selected
cases (Dauvilliers et al., 2010). Indeed, the H1N1 pandemic reached
Italy only in May 2009 and none of our cases occurred after H1N1
vaccination (http://www.who.int/csr/don/2009_05_03a/en/index.
html). Rather, increased diagnosis in our Sleep Disorders Center
may reflect increased awareness of narcolepsy with cataplexy
linked to a media campaign by the Italian association of narcoleptic
patients (Plazzi et al., 2006, 2008b; Serra et al., 2008). Group A
b-haemolytic streptococcus infections have been reported as pos-
sible environmental triggers for narcolepsy with cataplexy by several
studies (Aran et al., 2009; Dauvilliers et al., 2010; Koepsell et al.,
2010). In this context, childhood narcolepsy with cataplexy could be
therefore considered related to brain autoimmune post-
streptococcal diseases such as Sydenham’s chorea, obsessive-
compulsive disorder, tics and PANDAS (Dale, 2005). All these
conditions share an episodic course, a childhood-onset with acute
presentation, and coexistence of motor and behavioural symptoms.
Table 4 Spearman’s correlation coefficients between
composite scores of negative and active motor features
and clinical and investigational parameters of narcolepsy
with cataplexy
Clinical and
investigational
parameters
Negative Active
Baseline Trigger Baseline Trigger
Age at narcolepsy with cataplexy onset
 value 0.511 0.330 0.128 0.158
P-value 0.001 0.043 0.437 0.343
Disease duration
 value 0.493 0.657 0.277 0.501
P-value 0.001 50.0005 0.088 0.001
Multiple Sleep Latency Test
Sleep latency
 value 0.284 0.153 0.216 0.163
P-value 0.079 0.358 0.187 0.329
Sleep-onset REM periods
 value 0.042 0.026 0.062 0.051
P-value 0.801 0.875 0.709 0.762
Hypocretin-1
 value 0.119 0.059 0.067 0.120
P-value 0.555 0.774 0.738 0.559
Anti-streptolysin O
 value 0.153 0.182 0.284 0.220
P-value 0.374 0.296 0.093 0.205
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It is also notable that when narcolepsy with cataplexy is misdiag-
nosed, a choreiform movement disorder is often proposed as the
cause: PANDAS and Sydenham’s chorea were previous diagnoses in
our case series and an initial diagnosis of Huntington’s chorea was
reported in the first paediatric case series (Yoss and Daly, 1960).
Moreover, typical characteristics of narcolepsy with cataplexy are
reported in Sydenham’s chorea, such as being ‘clumsy’, ‘with-
drawn’, ‘troubled’, ‘day-dreaming’, ‘transient intellectual impair-
ment’ and ‘having nightmares’ (Gatti and Rosenheim, 1969;
Cimaz et al., 2010). Strikingly, motor impersistence demonstrated
by ptosis or tongue protrusion is a common sign in Sydenham’s
chorea, a condition also frequently associated with grimacing and
hypotonia (Oosterveer et al., 2010), and recurs in ‘cataplectic facies’
(Serra et al., 2008; Dhondt et al., 2009; Merino-Andreu and
Martinez-Bermejo, 2009). Finally, the motor signs of Sydenham’s
chorea tend to vanish within a few years from onset in most
cases (Cardoso et al., 2006), mirroring our cross-sectional observa-
tion in narcolepsy with cataplexy. Whether or not the choreic fea-
tures of recent-onset narcolepsy genuinely reflect a post-
streptococcal disorder deserves additional investigation.
In conclusion, we report that childhood narcolepsy with cata-
plexy when close to disease onset frequently manifests with a
movement disorder. Some of the clinical features of this complex
movement disorder are reminiscent of chorea and some patients
have high anti-streptolysin O titres. These movement abnormal-
ities seem transient, and the clinical phenotype may rapidly evolve
into a more characteristic picture that includes typical cataplexy.
The rapid loss of hypocretin neurons is likely to be involved in the
pathophysiology of the movement disorder, with the possible in-
volvement of secondary dopaminergic abnormalities.
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